JJDC
Profile, fund size and portfolio
JJDC is the corporate venture arm of Johnson & Johnson (healthcare). It was founded in 1973 and is based in New Brunswick, United States. It invests from Series A to Series C+ in oncology, immunology, neuroscience.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Series A to Series C+ |
| Sectors | Oncology, Immunology, Neuroscience, Ophthalmology, Medtech, Consumer health |
| Geography | North America, Europe, Asia (Portfolio companies by region, from the firm's portfolio page) |
| Offices | New Brunswick, United States, London, United Kingdom, San Francisco, United States, San Diego, United States, Cambridge, United States |
Sources: S9 Johnson & Johnson Innovation news feed (public JSON used by the site); S3 JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investments.
Data behind this graphic
| Item | Companies | Share |
|---|---|---|
| North America | 19 | 63.3% |
| Europe | 8 | 26.7% |
| Asia | 3 | 10% |
Portfolio companies by region, from the firm's portfolio page
Sources: S9 Johnson & Johnson Innovation news feed (public JSON used by the site); S3 JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investments.
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | USD 3.4bn+ | Cumulative invested | Stated by the firm or its parent | S11 |
| Companies backed | 100+ | companies | Reported in the press | S13 |
| IPOs | 28+ | IPOs | Stated by the firm | S15 |
| Companies on the firm's portfolio page | 27 | companies | Counted from the firm's own list | S3 |
Sources: S11 Global Venturing Powerlist 2025: Chris Picariello; S13 LinkedIn post by J&J Innovation (Jan 2025): 50 new and follow-on investments in 2024; S15 SEC EDGAR full-text search: 'Johnson & Johnson Innovation - JJDC'; S3 JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investments.
Where it invests and who leads it
Geography
- Headquarters
- New Brunswick, United States
- Offices
- New Brunswick, United States
- London, United Kingdom
- San Francisco, United States
- San Diego, United States
- Cambridge, United States
Portfolio companies by regionS9S3
Portfolio companies by region, from the firm's portfolio page
LeadersS4S6S5S7S8
- Chris PicarielloPresident, JJDCFind on LinkedInFirm page
- Fiona MacLaughlinVice President, Venture InvestmentsLinkedInFirm page
- Tamir MeiriPrincipal, Venture InvestmentsLinkedInFirm page
- Sanjay MistryVice President, Venture Investments, New Company CreationFind on LinkedInFirm page
- Nancy OndovikPrincipal, New Company CreationFind on LinkedInFirm page
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Johnson & Johnson (NYSE: JNJ) | Single source | S10 |
| Parent industry | Healthcare | Single source | S10 |
| Founded | 1973 | Single source | S10 |
| Headquarters | New Brunswick, United States | Single source | S3 |
| Status | Active | Single source | S1 |
| Capital source | Parent company only | Single source | S10 |
| Headline size | USD 3.4bn+ (Cumulative invested) | Single source | S11 |
| Companies backed | 100+ | Single source | S13 |
| Exits | 28 IPOs | Single source | S15 |
| People on the team page | 10 | Single source | S3 |
| Stages | Series A, Series C+ (inferred from announced rounds) | Estimate | S9 |
Recent rounds
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
Portfolio
The firm's portfolio page lists 27 companies: 27 active.S3
The firm also states 100+ companies backed. The page list and the stated total measure different things.S13
Every company on the JJDC list
27 companies, as listed on the firm's own website.S3 Read the firm's list.
- Abdera Therapeutics
- Accent Therapeutics
- Ankyra Therapeutics
- Arialys Therapeutics
- Aro Biotherapeutics
- Artera
- Asgard Therapeutics
- Astraveus
- AviadoBio
- Bright Peak Therapeutics
- Cellular Origins
- CirCode Biomed
- Citryll
- DAC Biotech
- EpiBiologics
- Flindr Therapeutics
- LinkCell Therapeutics
- Mestag Therapeutics
- Nucleome Therapeutics
- ONL Therapeutics
- PAQ Therapeutics
- Perceive Bio
- Prazer Therapeutics
- Rondo Therapeutics
- SonoThera
- Stylus Medicine
- TRexBio
History
Where sources disagree
- Portfolio count: 100+ active companies (J&J Innovation, 2024 year in review as reported by Global Venturing) (S11) vs 468 investments and acquisitions (PitchBook, prior profile) (S14) vs 167 (JJDC) and 118 (J&J Innovation) recorded investments (FundingWatcher, 28 Sep 2026) (S14). Entity naming changes database counts.S11S14S14
- Exits 2024 2025: Nine venture exits in 2024 (Global Venturing Powerlist 2025) (S11) vs 2025 portfolio M&As listed: Datavant (May, undisclosed), USD 2.1B AbbVie (Jun), USD 81.25M Tempus (Aug) (JJDC one-pager) (S3). Company names for the June and August deals are not printed in the PDF text.S11S3
Official pages
Read the firm's own pages for current information.
- Website jnjinnovation.com/venture-investing-jjdc
Sources
- S1Johnson & Johnson Innovation: Venture investing at JJDCFirm
- S3JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investmentsFirm
- S4Johnson & Johnson Innovation: Chris PicarielloFirm
- S5Johnson & Johnson Innovation: Tamir MeiriFirm
- S6Johnson & Johnson Innovation: Fiona MacLaughlinFirm
- S7Johnson & Johnson Innovation: Sanjay MistryFirm
- S8Johnson & Johnson Innovation: Nancy OndovikFirm
- S9Johnson & Johnson Innovation news feed (public JSON used by the site)Firm
- S10Global Venturing: How Johnson & Johnson Innovation lasted 50 decades (27 Oct 2022)Press
- S11Global Venturing Powerlist 2025: Chris PicarielloPress
- S12Global Venturing: J&J picks Picariello to replace Heyman (20 Nov 2019)Press
- S13LinkedIn post by J&J Innovation (Jan 2025): 50 new and follow-on investments in 2024Press
- S14FundingWatcher corporate venture capital listThird-party report
- S15SEC EDGAR full-text search: 'Johnson & Johnson Innovation - JJDC'Filing
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by JJDC or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.